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Atherosclerotic CVD arises from a macrophage-driven 
inflammatory response to modified LDL in the arterial 
wall. This view has received strong support from the 
positive outcome of the CANTOS trial (Canakinumab 
Abstract Activation of macrophage inflamma-
somes leads to interleukin (IL)-1 and IL-18 se-
cretion and promotes atherosclerosis and its 
complications in mice and humans. However, the 
specific role and underlying mechanisms of the in-
flammasome in atherogenesis are topics of active 
research. Several studies in hyperlipidemic mouse 
models found that the NOD-like receptor protein 
3 (NLRP3) inflammasome contributes to athero-
sclerosis, but recent work suggests that a second 
hit, such as defective cholesterol efflux or accumu-
lation of oxidized mitochondrial DNA, may be re-
quired for significant inflammasome activation. 
Cholesterol crystal uptake or formation in lyso-
somes may damage membranes and activate 
NLRP3 inflammasomes. Alternatively, plasma or 
ER membrane cholesterol accumulation may con-
dition macrophages for inflammasome activation 
in the presence of danger-associated molecular 
patterns, such as oxidized LDL. Inflammasome 
activation in macrophages or neutrophils leads to 
gasdermin-D cleavage that induces membrane 
pore formation, releasing IL-1 and IL-18, and 
eventuating in pyroptosis or neutrophil extracellu-
lar trap formation (NETosis). In humans, inflammasome activation and NETosis may contribute to atherosclerotic plaque ero-
sion and thrombosis, especially in patients with type 2 diabetes, chronic kidney disease, or clonal hematopoiesis.  Suppression 
of the inflammasome by activation of cholesterol efflux or by direct inhibition of inflammasome components may benefit pa-
tients with CVD and underlying susceptibility to inflammasome activation.—Tall, A. R., and M. Westerterp. Inflammasomes, 
neutrophil extracellular traps, and cholesterol. J. Lipid Res. 2019. 60: 721–727.
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Antiinflammatory Thrombosis Outcome Study), involving 
administration of an interleukin (IL)-1 antibody to patients 
with elevated levels of C-reactive protein (CRP) (1). IL-1 













722 Journal of Lipid Research Volume 60, 2019
and neutrophil entry into sites of inflammation. IL-1 is 
synthesized as a pro-form that undergoes proteolytic cleav-
age by CASPASE-1 in the inflammasome, a protein com-
plex assembled in the cytosol of macrophages in response 
to pathogen-associated molecular patterns or danger-asso-
ciated molecular patterns, leading to secretion of the active 
form of IL-1. The pro-form of IL-18 is similarly processed 
by inflammasomes resulting in IL-18 secretion (2). Together 
with preclinical studies (3–7), CANTOS points to a role of 
inflammasomes in atherothrombotic disease.
This review will discuss the role of inflammasomes in ath-
erosclerosis and the mechanisms underlying inflamma-
some activation in response to cholesterol accumulation in 
macrophages and neutrophils. Typical for an emerging 
area, several aspects of these studies are controversial. We 
will also discuss a potential link between inflammasomes 
and plaque neutrophil extracellular trap formation (NETo-
sis). NETosis involves the release of chromatin and granule 
contents from neutrophils, giving rise to large extracellular 
webs containing DNA, proteases, and myeloperoxidase that 
help to trap and inactivate pathogens (8). NETosis has been 
implicated in atherothrombosis, notably in plaque erosion 
and thrombosis (9, 10), a process that may be increasingly 
important in acute coronary syndromes (11).
MECHANISMS OF INFLAMMASOME ACTIVATION
The NOD-like receptor protein 3 (NLRP3) inflamma-
some is activated by a wide variety of microbial and meta-
bolic signals. This involves a priming step mediated by 
Toll-like receptors (TLRs) that leads to increased expres-
sion of Il-1, and the inflammasome components, Caspase-1 
and Nlrp3, followed by an activation step in which the com-
ponents of the inflammasome assemble in the cytoplasm 
and CASPASE-1 is cleaved (2). A variety of stimuli, includ-
ing extracellular ATP, silica particles, uric acid crystals, or 
cholesterol crystals, can activate the NLRP3 inflammasome. 
Activation involves a sensor (NLRP3) that assembles with an 
adaptor [adaptor protein apoptosis-associated speck-like 
protein containing CARD (ASC)] and forms a filamentous 
structure that provides a platform for CASPASE-1 cleavage 
(12). The NLRP3 inflammasome seems to sense membrane 
damage (13), which may lead to K+ efflux and mitochon-
drial reactive oxygen species (ROS) generation. Recent 
studies have shown that priming [in response to lipopoly-
saccharide (LPS)] involves the induction of mitochondrial 
DNA synthesis, including the enzyme mitochondrial deoxy-
ribonucleotide kinase [uridine/cytidine monophosphate 
kinase 2 (UMP-CMPK2)], while activation in response to 
ATP or nigericin leads to the oxidation and release of mito-
chondrial DNA that binds and activates the NLRP3 inflam-
masome (14). However, it is not yet clear that this represents 
a universal mechanism of NLRP3 inflammasome activation. 
NLRP3 inflammasome activation can occur without evident 
mitochondrial ROS generation or lysosomal damage (7, 
13), and, moreover, in some models, mitochondrial ROS 
generation is prevented by NLRP3 deficiency (15), suggesting 
that ROS can be generated downstream of inflammasome 
activation. Cytosolic double-stranded DNA introduced by 
microbes or formed in response to mitochondrial damage 
activates the NLRP3 inflammasome in human myeloid cells 
(16) and the absent in melanoma 2 (AIM2) inflammasome 
in mice (17). Deficiency of 25-hydroxycholesterol, a sup-
pressor of cholesterol biosynthesis, triggers release of DNA 
from mitochondria, AIM2 inflammasome activation, and 
secretion of IL-1 and IL-18 (18). The noncanonical in-
flammasome is responsible for mortality during LPS-induced 
sepsis (13). This involves activation of cytosolic CASPASE-11, 
possibly in response to direct binding of LPS or oxidized 
lipids (19). Active CASPASE-11 can induce NLRP3-mediated 
CASPASE-1 cleavage (13), likely as a consequence of mem-
brane damage and, thus, indirectly promote IL-1 and 
IL-18 cleavage.
INFLAMMASOMES, PYROPTOSIS, AND NETosis
Inflammasome activation can lead to pyroptosis, an in-
flammatory mode of cell death involving osmotic swelling, 
cell necrosis, and release of IL-1 and IL-18 as well as vari-
ous danger-associated molecular patterns, such as IL-1, 
high-mobility group box 1 (HMGB1) proteins, and ATP. 
Activated CASPASE-1 or CASPASE-11 cleave gasdermin-D 
(GSDMD), releasing an N-terminal fragment that forms 
membrane pores facilitating release of the aforementioned 
molecules, and likely as pores grow larger, eventuating in 
pyroptosis (20). Remarkably, a similar process in neutro-
phils, requiring inflammasome activation and GSDMD 
cleavage, leads to granule membrane dissolution, chroma-
tin decondensation, plasma membrane leakiness, and 
expulsion of DNA and proteases, a process apparently 
identical to NETosis (21, 22).
INFLAMMASOMES AND ATHEROSCLEROSIS
The role of the NLRP3 inflammasome in atherosclerosis 
was first explored by Duewell et al. (3). They found a major 
impact of the NRLP3 inflammasome on early lesion area in 
Western-type diet (WTD)-fed Ldlr/ mice that had been 
transplanted with bone marrow (BM) deficient in the key 
inflammasome components, Asc or Nlrp3. In contrast, 
Menu et al. (23) did not find any impact of whole-body 
deficiency of Asc, Nlrp3, or Caspase-1/11 on the size of ad-
vanced atherosclerotic lesions in WTD-fed Apoe/ mice. 
While some subsequent studies appeared to confirm the 
report of Duewell et al. (3) (see 4, 6, 24, 25), our own (7) 
and other studies (5) found no impact of deletion of the 
key inflammasome components, Nlrp3 or Caspase-1/11, on 
the area or morphology of either early or advanced lesions 
in WTD-fed Ldlr/ mice. The reason for the discrepant 
results is unknown; although unlike the studies by Duewell 
et al. (3), we did not find signs of inflammasome activation 
in Ldlr/ mice (7). When additional mutations that caused 
macrophage inflammasome activation, such as myeloid de-
ficiency of ABCA1 and ABCG1 or hematopoietic deficiency 
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mice, the NLRP3 inflammasome was clearly activated, as 
shown by increased CASPASE-1 cleavage, and did contrib-
ute to lesion area and macrophage content (5, 7). ABCA1 
and ABCG1 are the principal transporters mediating cho-
lesterol efflux from macrophages (26), indicating a role of 
defective cholesterol efflux in inflammasome activation. 
The 8-oxoguanine glycosylase is the main enzyme mediat-
ing repair of mitochondrial oxidized DNA that accumu-
lates in atherosclerotic lesions and may directly activate 
the NLRP3 inflammasome (27). The AIM2 inflammasome 
may also promote atherogenesis: double-stranded DNA 
was found in lesional cells, and deficiency of hematopoietic 
AIM2 resulted in an increase in smooth muscle cells, col-
lagen, and fibrous cap thickness, and a decrease in the ne-
crotic area of advanced lesions in Apoe/ mice (28).
Duewell et al. (3) showed that cholesterol crystals could 
induce macrophage NLRP3 inflammasome activation in 
vitro and related their in vivo findings to tiny cholesterol 
crystals detected in early foam cell lesions by confocal re-
flectance microscopy. However, prior studies by Small and 
Shipley (29) based on lipid phase behavior and observa-
tion of fresh plaques by polarized microscopy under tem-
perature-controlled conditions suggested that early foam 
cell lesions did not contain cholesterol crystals. Rather, 
such lesions contained liquid or liquid crystalline choles-
teryl esters that undergo artifactual crystal formation when 
cooled below body temperature (29). Thus, while choles-
terol crystals in advanced lesions may be involved in inflam-
masome activation, in our opinion, a role of cholesterol 
crystals in early foam cell lesions is questionable.
NETosis AND ATHEROSCLEROSIS
The formation of neutrophil extracellular traps (NETs) 
promotes venous and arterial thrombosis in mice (30–33). 
NETs promote atherosclerosis and carotid thrombosis in 
Apoe/ mice, as shown using chloramidine, a chemical in-
hibitor of NET formation (34). A recent study using mice 
with knockouts of peptidyl arginine deiminase 4 (PAD4), 
an essential enzyme in histone citrullination, suggested no 
impact of NETs on lesion area or macrophage content 
in early foam cell lesions in WTD-fed Ldlr/ mice, even 
though NETs were detected in lesions (9). In the same 
study, deficiency of PAD4 led to decreased neutrophil 
adherence, arterial injury, and thrombosis in the setting 
of disturbed carotid arterial flow, consistent with a role of 
NETosis in plaque erosion (9). These findings may have 
relevance to humans because NETs have been associated 
with unstable human atherosclerotic plaques, especially in 
regions of superficial erosion (10). In contrast to these 
studies, myeloid PAD4 deficiency did have an impact on 
lesion area in Apoe/ mice (35). Thus, like inflammasome 
activation, NETs seem to contribute to plaque develop-
ment and complications under specific experimental con-
ditions. As noted above, inflammasomes and NETs may be 
mechanistically interdependent. One study reported that 
cholesterol crystals could promote NET release that in turn 
promoted macrophage inflammasome activation (36). 
However, the conclusion that NETosis causes inflamma-
some activation has been questioned (33, 37). Our findings 
rather suggest that NETosis may be downstream of inflam-
masome activation in atherosclerosis (7). This conclusion 
is consistent with studies showing that inflammasome-
dependent pyroptosis and NETosis are similar processes 
dependent on GSDMD (21, 22). We speculate that neutrophil 
inflammasome activation may induce pyroptosis/NETosis 
in murine atherosclerosis and perhaps contribute to plaque 
erosion and thrombosis in humans.
INFLAMMASOME ACTIVATION IN MICE WITH 
DEFECTIVE CHOLESTEROL EFFLUX PATHWAYS IN 
MYELOID OR DENDRITIC CELLS
To interrogate a potential role of defective cholesterol 
efflux pathways in macrophage inflammasome activation, 
we bred mice with myeloid knockout of Abca1 and Abcg1 
using LysM-Cre transgenic mice. These MylABCDKO mice were 
bred with NLrp3/ or Caspase1/11/ mice and BM 
was transplanted into Ldlr/ recipients (7). MylABCDKO  
BM-transplanted Ldlr/ mice fed WTD showed promi-
nently increased levels of plasma IL-18, a marker of inflam-
masome activation, increased caspase-1 cleavage, and IL-1 
and IL-18 secretion by splenocytes. These findings were 
reversed by hematopoietic Nlrp3 or Caspase1/11 deficiency, 
indicating activation of the NLRP3 inflammasome in 
Ldlr/ mice with myeloid Abca1/Abcg1 deficiency (7). 
Nlrp3 or Caspase-1/11 deficiency decreased atherosclerotic 
lesion size in female MylABCDKO BM-transplanted Ldlr/ 
mice, particularly in early lesions (7).
Unexpectedly, there was marked neutrophil accumula-
tion in early plaques of Ldlr/ mice with myeloid Abca1/
Abcg1 deficiency and extensive NETosis (shown by coinci-
dent staining of neutrophil markers, myeloperoxidase, 
and citrullinated histones). Neutrophil accumulation and 
NETosis were reversed by hematopoietic Nlrp3 or Cas-
pase-1/11 deficiency, indicating that inflammasome activa-
tion promotes neutrophil recruitment and NETosis in 
early atherosclerotic plaques. These findings are consistent 
with evidence that neutrophils contribute to early plaque 
formation (33, 38). The genetic dependence of plaque 
NETosis on the NLRP3 inflammasome and caspase-1/11 
in MylABCDKO mice might be due to inflammasome activa-
tion in neutrophils. Notably, Abca1/Abcg1-deficient neutro-
phils showed increased cholesterol content and increased 
cleavage of caspase-1 and caspase-11 (7), which could lead 
to GSDMD cleavage and pyroptosis/NETosis. We were not 
able to detect increased Caspase-1 or -11 cleavage in cells 
isolated from plaques of MylABCDKO BM-transplanted Ldlr/ 
mice (7). This may reflect technical limitations and the 
lack of authentic reagents for detection of inflammasome 
activation in tissues. Alternatively, the effects of the inflam-
masome could be mediated through systemic effects, for 
example by the impact of IL-1 derived from macrophages 
on neutrophil activation and entry into plaques (39).
In contrast to myeloid Abca1/Abcg1 deficiency, we found 
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mice) in normolipidemic chow-fed mice markedly pro-
moted NLRP3 inflammasome activation, with a distinct 
phenotype of auto-immune inflammation and a lupus-like 
syndrome (40). Similar to cholesterol-25-hydroxylase-
deficient mice that also show increased autoimmunity 
(41), DCABCDDKO mice showed prominent induction of Th17 
cells (40), probably secondary to release of inflammatory 
cytokines from dendritic cells, including IL-1. Thus, in-
flammasome activation due to disturbances of cholesterol 
homeostasis in dendritic cells can connect innate and ac-
quired immune systems and promote auto-immunity.
MECHANISMS OF INFLAMMASOME ACTIVATION BY 
CHOLESTEROL
On a mechanistic level, myeloid Abca1/Abcg1 deficiency 
led to increased expression of Nlrp3, Caspase-1, and Il-1 in 
CD11b+ splenocytes, consistent with earlier findings showing 
plasma membrane cholesterol enrichment and increased 
TLR4 signaling in Abca1/Abcg1-deficient macrophages (42) 
and indicative of inflammasome priming. There was promi-
nent accumulation of cholesterol in lysosomes and a small 
increase in refractile material inside these cells, as detected 
by confocal reflectance microscopy (7). Sheedy et al. (43) 
showed that CD36-mediated uptake of oxidized LDL by mac-
rophages can lead to formation of cholesterol crystals in 
lysosomes leading to lysosomal damage and NLRP3 inflam-
masome activation. However, in MylABCDKO macrophages, 
there was no evidence of lysosomal damage or increased mi-
tochondrial ROS in splenic monocytes, macrophages, and 
neutrophils. Searching for alternative mechanisms to explain 
NLRP3 inflammasome activation, we discovered that my-
eloid Abca1/Abcg1 deficiency also activated the noncanonical 
inflammasome (7). Moreover, there was increased suscepti-
bility to LPS-induced death in MylABCDKO mice, which was res-
cued by Caspase-1/11 deficiency but not by Nlrp3 deficiency, a 
signature of noncanonical inflammasome activation (7). Ac-
tivation of the noncanonical inflammasome can lead to 
NLRP3 inflammasome activation (44), providing a potential 
mechanism to explain NLRP3 inflammasome activation. 
However, this is unlikely to be a complete explanation for the 
dramatic activation of the NLRP3 inflammasome in MylABCDKO 
mice.
A NEW MODEL TO EXPLAIN STEROL-DEPENDENT 
INFLAMMASOME ACTIVATION
Recent studies have shown that macrophages from 
Niemann-Pick C1 (Npc1)-deficient mice, that display promi-
nent lysosomal cholesterol accumulation similar to 
MylABCDKO macrophages, are protected from NLRP3 inflam-
masome activation; these studies suggested that ER rather 
than lysosomal cholesterol accumulation promotes inflam-
masome activation (45) (Fig. 1). Our earlier studies in 
Abca1/Abcg1-deficient macrophages suggested that these 
cells have increased ER cholesterol content, as shown by 
reduced expression of the SREBP2 target genes, Hmgcr and 
Ldlr (46). Moreover, macrophages deficient in cholesterol-
25-hydroxylase that likely have increased ER cholesterol 
content due to derepression of SREBP2 processing and in-
creased cholesterol biosynthesis show increased NLRP3, 
AIM2, and NLRC4 inflammasome activation (41). Together 
these observations suggest that ER or plasma membrane 
cholesterol accumulation may promote the assembly of dif-
ferent inflammasome sensors with ASC leading to inflam-
masome formation. It is likely that an additional activation 
signal is required to produce NLRP3 inflammasome activa-
tion. We speculate that, in atherosclerosis, this may be de-
pendent on the uptake or recognition of lipoprotein-derived 
oxidized phospholipids or oxysterols by macrophages.
HUMAN RELEVANCE
Whole-body Abca1 deficiency induced NLRP3 inflamma-
some activation in Ldlr/ mice, while myeloid deficiency 
of Abca1 did not (7). Only the former is associated with low 
HDL levels (26), indicating that myeloid Abca1 deficiency 
combined with low HDL levels is sufficient to induce in-
flammasome activation. This is presumably because the low 
HDL causes defective cholesterol efflux via non-ABCA1 
pathways such as ABCG1. Tangier disease (TD) patients 
who are homozygous for a loss-of-function of the ABCA1 
gene displayed elevated IL-18 plasma levels, showing hu-
man relevance (7). This suggests that low HDL, defective 
apoA-1, and reduced expression of ABCA1/ABCG1 in 
monocyte/macrophages may be sufficient to induce in-
flammasome activation in humans. Such changes occur 
commonly in patients with poorly controlled type 2 diabetes 
and chronic kidney disease and with ageing (47–53). TD 
patients sometimes present with premature atherosclerotic 
CVD (54); however, the more consistent phenotype among 
adult TD patients is peripheral neuropathy (55). A recent 
study has shown that defective myelin clearance due to 
microglial Abca1/Abcg1 deficiency promotes inflamma-
some activation and limits remyelination following a neu-
ronal injury in aged mice (56). Together with our findings, 
this suggests that macrophage inflammasome activation 
may be involved in the pathogenesis of peripheral neurop-
athy in TD and conceivably type 2 diabetes.
Clonal hematopoiesis involving variants in several genes 
that predispose to hematological malignancies, including 
loss-of-function epigenetic modifiers, such as TET2, or 
gain-of-function JAK/STAT signaling (JAK2V617F), has re-
cently emerged as a major risk factor for coronary heart 
disease, especially in the elderly (57, 58). Studies in mice 
with myeloid Tet2 deficiency have shown macrophage in-
flammasome activation leading to increased IL-1 produc-
tion and accelerated atherosclerosis (58, 59). NLRP3 
inflammasome activation is also prominent in splenic my-
eloid cells in JAK2V617F BM-transplanted Ldlr/ mice that 
have accelerated atherosclerosis with increased necrotic 
cores (60). NLRP3 inflammasome activation may promote 
atherosclerosis and thrombosis in JAK2V617F patients with 
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PERSPECTIVES FOR FUTURE STUDIES
New mechanistic and genetic studies may help to clarify 
the upstream signals and molecules involved in inflamma-
some activation and their relevance in metabolic diseases. 
There is a need to develop sensitive authentic reagents for 
detection of inflammasome activation in mouse and human 
tissues. This may help to distinguish local versus systemic 
effects of inflammasomes in atherogenesis and to evaluate the 
role of inflammasome activation and pyroptosis/NETosis 
Fig. 1. Inflammasome activation by lipids in macrophages and neutrophils. Step 1: NLRP3 inflammasome priming. Oxidized LDL (oxLDL) 
activates the TLR4, leading to activation of NF-B and transcription of NLRP3 and pro-IL-1. Step 2: Inflammasome activation. OxLDL is 
taken up via the scavenger receptor CD36 and hydrolyzed in the lysosome. Oxidized lipids that enter the cytosol activate the noncanonical 
inflammasome resulting in caspase-11 cleavage. In the absence of Abca1 and Abcg1, cholesterol accumulates in the plasma membrane and is 
then transported to the ER. ER cholesterol accumulation activates the NLRP3 inflammasome, resulting in caspase-1 cleavage and subsequent 
cleavage of pro-IL-1 and pro-IL-18. Step 3: GSDMD cleavage. The active (cleaved) forms of caspase-1 and caspase-11 cleave GSDMD, and its 
N-terminal form (GSDMD-NT) stimulates membrane pore formation. The NLRP3 inflammasome is also activated downstream of caspase-11 
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in plaque erosion and atherothrombosis. That different 
underlying risk factors for CVD (such as type 2 diabetes, 
chronic kidney disease, and clonal hematopoiesis) may 
mechanistically link to atherothrombosis via inflamma-
some activation could be evaluated in human observational 
studies, using plasma IL-18 levels or tissue samples to mea-
sure inflammasome activation. While the CANTOS sug-
gests a role for inflammasome-derived IL-1 in human 
CVD, the magnitude of the benefit was moderate, and 
there was an excess of infections associated with treatment 
(1), perhaps due to decreased neutrophil levels. It may be 
informative to determine whether elevated IL-18 levels or 
the presence of clonal hematopoiesis mutations help to de-
fine subgroups of patients who particularly benefitted from 
treatment. This may help to stratify patients in future 
clinical studies targeting NLRP3, noncanonical, or AIM2 
inflammasomes. On a therapeutic level, removal of choles-
terol from macrophages and neutrophils by infusion of 
reconstituted HDL particles, which are under clinical eval-
uation in a phase 3 clinical study (Aegis-II, NCT03473223), 
may alleviate inflammasome activation when administered 
after an acute coronary syndrome (61). LXR activators, 
perhaps targeted to myeloid cells in nanoparticles (62), 
could reduce inflammasome activation both by upregulat-
ing ABCA1/ABCG1 and by direct suppression of Il-l (63). 
Recent progress in inflammasome research suggests that 
molecules upstream of IL-1 secretion, such as NLRP3, cas-
pase-1/11, or CMPK2, may provide additional therapeutic 
targets for preventing CVD in patients with evidence of un-
derlying inflammasome activation.
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